The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Recovery from trauma can take a lot of time and hard work, but it’s absolutely possible. Here are seven reminders to carry with you during your trauma recovery journey. Since threats can involve ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, expectations were $1.99. Operator: Good morning and welcome to Johnson & Johnson ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

As the only major healthcare company focused both on pharmaceuticals and medical ... system, and advancements across our cardiovascular portfolio, including electrophysiology, heart recovery ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

To date, SPRAVATO has been administered to more than 140,000 patients worldwide. Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ... Licensed medical providers have also faced dwindling supplies ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...